Renal Manifestations of Rheumatoid Arthritis

作者: Teja Kapoor , Joan Bathon

DOI: 10.1016/J.RDC.2018.06.008

关键词: Systemic inflammationTofacitinibMethotrexateKidney diseaseIn patientRheumatoid arthritisAdverse effectDisease severityMedicineInternal medicine

摘要: Renal manifestations in rheumatoid arthritis (RA) have evolved as RA management has improved. In the past, older disease-modifying antirheumatic drugs, uncontrolled systemic inflammation, and chronic nonsteroidal antiinflammatory drug (NSAID) use contributed to kidney disease. Over time, of methotrexate biologic medications, decrease NSAID use, a treat-to-target strategy renal manifestations. Chronic disease now is more likely be caused by cardiovascular risk factors than severity. patients with dysfunction, NSAIDs, methotrexate, tofacitinib may need adjusted or avoided prevent adverse events.

参考文章(77)
Jasin He, Comer Ss, In vitro immunomodulatory effects of sulfasalazine and its metabolites. The Journal of Rheumatology. ,vol. 15, pp. 580- 586 ,(1988)
William E. Smoyer, Jeffrey S. Berns, George R. Aronoff, Nishaminy Kasbekar, Deborah A. Pasko, Bruce A. Mueller, Michael E. Brier, William M. Bennett, Drug prescribing in renal failure : dosing guidelines for adults and children American College of Physicians. ,(2007)
Harshna Patel, Aiala Barr, Khursheed N Jeejeebhoy, Renal effects of long-term treatment with 5-aminosalicylic acid Canadian Journal of Gastroenterology & Hepatology. ,vol. 23, pp. 170- 176 ,(2009) , 10.1155/2009/501345
B. E. E. M. Van Den Borne, B. A. C. Dijkmans, C. L. Verweij, H. H. De Rooij, S. Le Cessie, Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. The Journal of Rheumatology. ,vol. 24, pp. 55- 60 ,(1997)
J. P. Bonvalet, P. Pradelles, N. Farman, Segmental synthesis and actions of prostaglandins along the nephron. American Journal of Physiology-renal Physiology. ,vol. 253, ,(1987) , 10.1152/AJPRENAL.1987.253.3.F377
Daniel H. Solomon, Asaf Bitton, Jeffrey N. Katz, Helga Radner, Erika M. Brown, Liana Fraenkel, Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis & Rheumatism. ,vol. 66, pp. 775- 782 ,(2014) , 10.1002/ART.38323
A Muraguchi, M Iwano, H Ishikawa, T Matsuda, T Hirayama, K Dohi, Y Horii, Y Ohmoto, Y Fujii, H Yamada, Involvement of IL-6 in mesangial proliferative glomerulonephritis. Journal of Immunology. ,vol. 143, pp. 3949- 3955 ,(1989)
A. A. H. Lawson, N. Maclean, Renal disease and drug therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases. ,vol. 25, pp. 441- 449 ,(1966) , 10.1136/ARD.25.5.441
A. J Hueber, A. Tunc, G. Schett, B. Manger, Anti‐tumour necrosis factor α therapy in patients with impaired renal function Annals of the Rheumatic Diseases. ,vol. 66, pp. 981- 982 ,(2007) , 10.1136/ARD.2006.069211